The molecular staging of prostate cancer

BJU International

Volumn 94, Issue 9, 2004, Pages 1217-1220

  McIntyre, Iain G ^a,c   Hart, Claire A ^a   Brown, Michael D ^a   Ross, David G ^a   George, Nicholas J R ^b   Clarke, Noel W ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Micrometastasis; Prostate adenocarcinoma; RT PCR; Staging

Indexed keywords

CELL MARKER; COMPLEMENTARY DNA; DNA FRAGMENT; DNA POLYMERASE; MESSENGER RNA; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

BONE MARROW; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; EPITHELIUM CELL; FLOW CYTOMETRY; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOMAGNETIC SEPARATION; IN VITRO STUDY; LEUKOCYTE; METASTASIS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SHORT SURVEY;

BIOPSY; HUMANS; MALE; NEOPLASM STAGING; PROSTATE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING;

EID: 11144234982     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.05145.x     Document Type: Short Survey

References (24)

1. Albertsen PC, Hanley JA, Harlan LC et al. The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: a population based analysis. J Urol 2000; 163: 1138-43
2. Partin AW, Kattan MW, Subong NP et al. Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage of localised prostate cancer. JAMA 1997; 277: 1445-51
3. Vessella RL, Riley DE, Blouke KA, Arfman EW. A sensitive method for detection of prostate tumour cell marker using the polymerase chain reaction. J Urol 1992; 147: 441A
4. Fidler IJ. Critical factors in the biology of human cancer metastasis: Twenty eighth GHA Clowes Memorial Lecture. Cancer Res 1990; 50: 6130-8
5. Katz AE, Olsson CA, Raffo AJ et al. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 1994; 43: 765-75
6. Gao CL, Maheshwari S, Dean RC et al. Blinded evaluation of reverse transcriptase polymerase chain reaction prostate specific antigen peripheral blood assay for molecular staging of prostate cancer. Urology 1999; 53: 714-21
7. Ignatoff JM, Oefelein MG, Watkin W, Chmiel JS, Kaul KL. Prostate specific antigen reverse transcriptase polymerase chain reaction assay in preoperative staging of prostate cancer. J Urol 1997; 158: 1870-5
8. McIntyre IG, Spreckley K, Clarke RB, Anderson E, Clarke NW, George NJ. Optimization of the reverse transcriptase polymerase chain reaction for the detection of circulating prostate cells. Br J Cancer 2000; 83: 992-7
9. Henke W, Jung M, Jung K et al. Increased analytical sensitivity of RTPCR of PSA mRNA decreases diagnostic specificity of detection of prostate cells in blood. Int J Cancer 1997; 70: 52-6
10. de la Taille A, Olsson CA, Buttyan R et al. Blood-based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen: long term follow-up confirms the potential utility of this assay in identifying patients more likely to have biochemical recurrence (rising PSA) following radical prostatectomy. Int J Cancer 1999; 84: 360-4
11. Straub B, Muller M, Krause H et al. Detection of prostate-specific antigen RNA before and after radical retropubic prostatectomy and transurethral resection of the prostate using 'Light-Cycler'-based quantitative real-time polymerase chain reaction. Urology 2001; 58: 815-20
12. McIntyre IG, Clarke RB, Anderson E, Clarke NW, George NJ. Molecular prediction of progression in patients with conservatively managed prostate cancer. Urology 2001; 58: 762-6
13. Tombal B, Cangh PJ, Loric S, Gala JL. Prognostic value of circulating prostate cells in patients with a rising PSA after radical prostatectomy. Prostate 2003; 56: 163-70
14. Kantoff PW, Halabi S, Farmer DA, Hayes DF, Vogelzang NA, Small EJ. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. J Clin Oncol 2001; 19: 3025-8
15. Mejean A, Vona G, Nalpas B et al. Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumour recurrence. J Urol 2000; 163: 2022-59
16. Wood DP, Banks ER, Humphreys S, McRoberts JW, Rangnekar VM. Identification of bone marrow micrometastases in patients with prostate cancer. Cancer 1994; 74: 2533-40
17. Wood DP, Banerjee M. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol 1997; 15: 3451-7
18. Jung R, Ahmad-Nejad P, Wimmer M, Gerhard M, Wagener C, Neumaier M. Quality management and influential factors for the detection of single cells by reverse transcriptase polymerase chain reaction. Eur J Chem Clin Biochem 1997; 35: 3-19
19. Meye A, Bilkenroth U, Schmidt U et al. Isolation and enrichment of urologic tumor cells in blood samples by a semi-automated CD45 depletion autoMACS protocol. Int J Oncol 2002; 21: 521-30
20. Brandt B, Junker J, Griwatz C et al. Isolation of prostate derived cells and cell clusters from human peripheral blood. Cancer Res 1996; 56: 4556-61
21. Weckermann D, Muller P, Wawroschek F, Harzmann R, Riethmuller G, Schlimok G. Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. J Urol 2001; 166: 699-703
22. Bianco FJ Jr, Wood DP Jr, Gomes de Oliveira J, Nemeth JA, Beaman AA, Cher ML. Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer. Prostate 2001; 49: 235-42
23. Ghossein RA, Osman I, Bhattacharya S et al. Detection of prostatic specific membrane antigen messenger RNA using immunobead reverse transcriptase polymerase chain reaction. Diagn Mol Pathol 1999; 8: 59-65
24. Moreno JG, O'Hara SM, Gross S et al. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology 2001; 58: 386-92